Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.64 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234275 | 0.87 | CHRM1 (0.66) | CHRM1FABP4ATMALDH1A1KDM4E | |
| SCHEMBL2881818 | 0.86 | CHRM1 (0.73) | CHRM1FABP4ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2877658 | 0.85 | CHRM1 (0.62) | CHRM1LMNAKDM4C | |
| SCHEMBL2877481 | 0.85 | CHRM1 (0.86) | CHRM1MAPTLMNA | |
| SCHEMBL2877226 | 0.84 | CHRM1 (0.57) | CHRM1ALDH1A1KDM4EKMT2A | |
| SCHEMBL3242155 | 0.84 | CHRM1 (0.45) | CHRM1FABP4ATMALDH1A1KDM4E | |
| SCHEMBL2490851 | 0.83 | CHRM1 (0.79) | CHRM1FABP4ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2877807 | 0.83 | CHRM1 (0.74) | CHRM1ALDH1A1LMNA | |
| SCHEMBL2883219 | 0.83 | CHRM1 (0.76) | CHRM1FABP4ALDH1A1KDM4EMAPT | |
| SCHEMBL2883187 | 0.81 | CHRM1 (0.56) | CHRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | claimed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | claimed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2007067489-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, MTNR1A | CHRM1 1/4885FABP4 3265/4885ATM 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.